Company Overview
Gilead Sciences is a biotechnology company that develops and sells medicines. Its business is built around bringing therapies to market and supporting them through ongoing commercial distribution. The company operates at large scale, with a market capitalization around USD 171.5 billion. The investment debate tends to come down to how durable its economics are as it converts sales into earnings and cash.
Analysis of recent data
FundamentalsIn its latest annual period (10-K, reported USD figures), Gilead posted revenue of USD 29.4 billion and EBIT of USD 10.0 billion, translating into a business that converts a meaningful portion of sales into operating profit. Net income was USD 8.5 billion. Revenue grew 2.4% year over year in that period.
The cost structure implied by the margins is unusually favorable: 78.83% gross margin, 34.04% operating margin, and 28.91% net profit margin (TTM). Cash was USD 7.6 billion versus total debt of USD 5.6 billion at period end. A simple free-cash-flow proxy (that excludes working-capital changes) comes out to about USD 8.5 billion, with D&A of USD 370 million and CapEx of USD 563 million—numbers that matter because returns-
Valuation
DCF / MultiplesAt a current price of USD 138.11, the DCF work implies a fair value range that runs from slightly below the current price in a weaker outcome to well above it in a stronger outcome. In other words, today’s price does not require an aggressive upside case to make the valuation math work, but it also leaves less room for error if results drift toward the low end of the range.
The key tension is that the stock is priced at 20.14x trailing earnings (TTM). That multiple can be consistent with solid long-run returns, but it also means the market is paying for earnings durability rather than a single good year.
Conclusion
TakeawayThis looks like a reasonable opportunity today. The price leans on durable profitability and ongoing cash conversion. It doesn’t need a heroic outcome, but it does need the current economics to stick. The main thing that breaks the view is a sustained erosion in the business’s ability to turn sales into cash.